Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley says.
‘China’s Ozempic’ may vie with Eli Lilly, Novo Nordisk for global weight-loss drug market
RELATED ARTICLES
